We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus (CCL)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00626717
First Posted: February 29, 2008
Last Update Posted: January 17, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Peschke Meditrade, GmbH
Information provided by (Responsible Party):
D Dr. Philip Maier, University Hospital Freiburg
  Purpose

Background: Corneal cross linking is a procedure that induces collagen cross linking of the corneal stroma due to release of reactive oxygen radicals upon activation of topically applied riboflavine A by UVA exposure. This procedure might be capable of reducing keratocouns progression.

Purpose: Although there are no randomised controlled trials on the effectiveness of corneal cross linking for the treatment of keratoconus it gains more and more importance in the general clinical setting. Therefore, the investigators started such randomised, placebo controlled, double blinded, multicenter trial to find out if this treatment is as effective as it promises to be.

Methods: Randomised, placebo controlled, double blinded, multicenter trial.


Condition Intervention Phase
Keratoconus Procedure: Riboflavin/UVA crosslinking Procedure: Sham treatment Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus

Resource links provided by NLM:


Further study details as provided by D Dr. Philip Maier, University Hospital Freiburg:

Primary Outcome Measures:
  • Keratoconus progression [ Time Frame: 3 years ]
  • Endothelial cell loss [ Time Frame: 3 years ]

Enrollment: 30
Study Start Date: August 2007
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Procedure: Riboflavin/UVA crosslinking
Removal of epithelium. Riboflavin eye drops. UVA exposure.
Sham Comparator: 2 Procedure: Sham treatment
Fluorescein eye drops. Exposure with blue light

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Only early Keratoconus (Contact lens fitting)
  • Progression of Ametropia.
  • Corneal thickness > 450µm

Exclusion Criteria:

  • Further ophthalmic diseases
  • History of ocular surgery
  • Pregnancy, brest feeding
  • Allergy against Riboflavin
  • End stage Keratoconus
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00626717


Locations
Germany
University Eye Hospital Freiburg
Freiburg, Baden-Württemberg, Germany, 79106
Sponsors and Collaborators
University Hospital Freiburg
Peschke Meditrade, GmbH
Investigators
Principal Investigator: Philip Maier, MD University Eye Hospital, Freiburg
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: D Dr. Philip Maier, PD Dr. med., University Hospital Freiburg
ClinicalTrials.gov Identifier: NCT00626717     History of Changes
Other Study ID Numbers: FR-03-CCL
First Submitted: February 20, 2008
First Posted: February 29, 2008
Last Update Posted: January 17, 2013
Last Verified: January 2013

Keywords provided by D Dr. Philip Maier, University Hospital Freiburg:
Keratoconus
Cross linking
Riboflavin

Additional relevant MeSH terms:
Keratoconus
Corneal Diseases
Eye Diseases
Riboflavin
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Photosensitizing Agents
Dermatologic Agents